The purpose of this study is to explore the safety, preliminary clinical benefit, and activity of BIVV009 in patients with chronic immune thrombocytopenia. BIVV009 has been designed to block the pathway that triggers the immune system to remove damaged cells. It is believed that this approach may limit the number of cells immune system removes and allow the extra cells to help promote platelet production.

USA

https://clinicaltrials.gov/ct2/show/NCT03275454?recrs=a&cond=ITP&draw=4&rank=30

Recruiting